Tradestie Institutional Equity Comparison Engine

EQ vs AKTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EQ Overall Edge

EQ Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Options & Structure while AKTX counters with relative strength in Momentum & Technical. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus AKTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against AKTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
EQ 1.5x vs AKTX N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -52.3% vs +0.0%
Momentum & Technical Winner AKTX
1Y +12.0% vs +1163.7% ยท 52W Pos 11% vs 23%
Options & Structure Winner EQ
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
1M Return -21.13%
1Y Return +12.0%
Forward P/E 1.5x
Unified AI Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
AKTX NASDAQ
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$6.71
+0.9% 1D
Market Cap $16.3M
1M Return -23.4%
1Y Return +1163.65%
Forward P/E N/M
Unified AI Score
53.0 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EQ +12.0% AKTX +1163.65% Spread: +1151.65 pp (AKTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EQ TTM Op. Margin: 0.0% AKTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs AKTX. Trailing 12-month operating profitability (EQ 0.0% vs AKTX 0.0%) and valuation multiples (EQ 1.5x vs AKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EQ (5) vs AKTX (3)
Institutional Metric EQ AKTX Criterion Row Winner
Market Capitalization Scale $90.6M $16.3M Larger Scale EQ
Trailing P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Forward P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Revenue Growth (YoY) Growth -52.3% +0.0% Higher Growth AKTX
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.0% -146.3% Higher ROE EQ
52-Week Range Position Momentum 11% ($1โ€“$4) 23% ($0โ€“$29) Stronger Trend AKTX
Beta / 30D Volatility Risk Regime 1.53ฮฒ ยท 93% Vol 81.68ฮฒ ยท 145% Vol Lower Realized Risk EQ
Unified Institutional Score Composite Signal 48.0 / 100 (HOLD) 53.0 / 100 (HOLD) Higher Composite AKTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EQ vs AKTX Buy Guide
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AKTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EQ nor AKTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.